Automatic offer of shelved cancer assets to non-profits after two years
When a company stops developing a cancer drug for business reasons, the rights and data would automatically be offered to charities and universities on set terms after two years, so promising compounds do not disappear.
A legal or funder-imposed condition (for example on drugs that received public research funding, orphan designation or tax credits) that oncology assets discontinued for non-safety reasons and not actively developed for two years must be offered for licence to qualified non-profit or academic developers on pre-set terms (non-exclusive for research, exclusive for defined rare indications, modest royalties on commercialisation). Data packages and remaining drug supply are included. Companies retain rights to resume. This complements the stalled-asset registry by creating a duty, not just a listing.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaPatent-free open-source development of repurposed and off-patent cancer drugs
Shares A repurposing label pathway with short exclusivity that non-profits can hold, A non-profit pharmaceutical company for the cancers markets ignore.
- IdeaA shared compound library that rare cancer researchers can actually use
Shares Secrecy and intellectual property block collaboration, The valley of death between lab and product, Rare and paediatric cancers without markets.
- IdeaMilestone-based venture philanthropy with royalties recycled into the pipeline
Shares A non-profit pharmaceutical company for the cancers markets ignore, The valley of death between lab and product, Rare and paediatric cancers without markets.
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Secrecy and intellectual property block collaboration, Rare and paediatric cancers without markets.
- IdeaAdvance market commitments for paediatric and rare cancer drugs
Shares A non-profit pharmaceutical company for the cancers markets ignore, Rare and paediatric cancers without markets.
- IdeaScale up public drug development that takes academic assets to phase 1
Shares A non-profit pharmaceutical company for the cancers markets ignore, The valley of death between lab and product.
- IdeaA single oncology trial data trust with mandatory deposit within eighteen months
Shares A public registry of stalled academic assets and shelved company compounds, Secrecy and intellectual property block collaboration.
- IdeaAn open engineering platform for academic ADCs and bispecifics
Shares Secrecy and intellectual property block collaboration, The valley of death between lab and product.